NCT01423539WithdrawnPhase 2
A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Genentech, Inc.
- Primary Endpoint
- Progression-free survival (time from randomization to progression, relapse or death of any cause)
Study Overview
Brief Summary
This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically documented diagnosis of diffuse large B-cell lymphoma
- •Patients must have relapsed or developed progressive disease following salvage therapy, or must have relapsed or progressed following initial therapy and in the opinion of the investigator are medically unfit to receive high dose chemotherapy with autologous stem cell transplant (SCT) or other salvage therapy of higher priority
- •Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- •Patients who have undergone STC must be more than 100 days from autologous stem cell infusion prior to first dose of study drug, must have recovered from any transplant related toxicity and must have adequate bone marrow function as defined by protocol independent of any growth factor support
- •Patients who have not undergone SCT must have adequate bone marrow function as defined by protocol independent of any growth factor support
- •Adequate coagulation, renal and hepatic function
Exclusion Criteria
- •Refractory DLBCL
- •History of other malignancies within 2 years prior to initiation of study treatment except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, low-grade localized prostate cancer treated surgically with curative intent or one that carries a good prognosis, in situ ductal carcinoma of the breast treated with lumpectomy (with and without radiation) with curative intent
- •Active infection requiring parenteral antibiotics or antiviral or antifungal agents
- •Inherited or acquired bleeding diathesis, anticoagulant drugs or drugs that inhibit platelet function, underlying conditions that predisposes to abnormal bleeding, or refractoriness to platelet transfusions
- •Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, or ventricular tachyarrhythmias requiring medication within 1 year prior to the initiation of study treatment
- •Positive for hepatitis B, hepatitis C or HIV infection
Arms & Interventions
B
Experimental
Intervention: navitoclax (Drug)
A
Active Comparator
Intervention: bendamustine (Drug)
A
Active Comparator
Intervention: rituximab (Drug)
B
Experimental
Intervention: bendamustine (Drug)
B
Experimental
Intervention: rituximab (Drug)
Outcomes
Primary Outcomes
Progression-free survival (time from randomization to progression, relapse or death of any cause)
Time Frame: up to approximately 33 months
Secondary Outcomes
- Duration of response(approximately 33 months)
- Clinical response rates (complete response/partial response/stable disease)(approximately 33 months)
- Overall survival(approximately 33 months)
- Safety: Incidence of adverse events(approximately 33 months)
Investigators
Similar Trials
Completed
Phase 2
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisMyelofibrosis (MF)NCT03222609AbbVie191
Terminated
Phase 2
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerNCT03584009Hoffmann-La Roche103
Recruiting
Phase 2
VA vs DA for Newly Diagnosed Hig-risk AMLAcute Myeloid LeukemiaNCT05939180The First Affiliated Hospital of Soochow University116
Active, not recruiting
Phase 1
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeMyelodysplastic SyndromeNCT05564650Thomas Jefferson University6
Active, not recruiting
Phase 1
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT05222984City of Hope Medical Center17